Regional citrate anticoagulation in critically ill patients with liver and kidney failure

Journal of Nephrology

Volumn 25, Issue 1, 2012, Pages 113-119

  Balogun, Rasheed A ^a   Turgut, Faruk ^a   Caldwell, Stephen ^a   Abdel Rahman, Emaad M ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Circuit clotting; Circuit lifespan; Continuous renal replacement therapy; Dialysis; Hypocalcemia; Metabolic alkalosis; Regional citrate anticoagulation

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BICARBONATE; CALCIUM ION; CITRIC ACID; SODIUM; ANTICOAGULANT AGENT; CALCIUM;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULATION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BICARBONATE BLOOD LEVEL; CALCIUM BLOOD LEVEL; CIRCUIT LIFESPAN; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; FEMALE; HOSPITAL DISCHARGE; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LIVER DYSFUNCTION; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MODEL FOR END STAGE LIVER DISEASE SCORE; OUTCOME ASSESSMENT; PATIENT SAFETY; REGIONAL CITRATE ANTICOAGULATION; RETROSPECTIVE STUDY; SCORING SYSTEM; SODIUM BLOOD LEVEL; SURVIVAL; SURVIVAL TIME; ACUTE KIDNEY FAILURE; BLOOD; END STAGE LIVER DISEASE; HOSPITALIZATION; INTENSIVE CARE; MIDDLE AGED; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY; TIME;

ACUTE KIDNEY INJURY; ADULT; ALANINE TRANSAMINASE; ANTICOAGULANTS; ASPARTATE AMINOTRANSFERASES; BICARBONATES; CALCIUM; CITRIC ACID; CRITICAL CARE; END STAGE LIVER DISEASE; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84862247415     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2011.8363     Document Type: Article

References (20)

1. Abosaif NY, Tolba YA, Heap M, et al. The outcome of acute renal failure in the intensive care unit according to RIFLE: Model application, sensitivity, and predictability. Am J Kidney Dis. 2005;46:1038-1048.
2. Metnitz PG, Krenn CG, Steltzer H, et al. Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. Crit Care Med. 2002;30:2051-2058.
3. Uchino S, Kellum JA, Bellomo R, et al; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA. 2005;294:813-818.
4. Bagshaw SM, Laupland KB, Boiteau PJ, et al. Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional critical care system. J Crit Care. 2005;20:155-161.
5. Oudemans-van Straaten HM, Bosman RJ, Koopmans M, et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med. 2009;37:545-552.
6. Swartz R, Pasko D, O'Toole J, et al. Improving the delivery of continuous renal replacement therapy using regional citrate anticoagulation. Clin Nephrol. 2004;61:134-143.
7. Mehta RL, McDonald BR, Aguilar MM, et al. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int. 1990;38:976-981.
8. Tolwani AJ, Prendergast MB, Speer RR, et al. A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance. Clin J Am Soc Nephrol. 2006;1:79-87.
9. Gabutti L, Marone C, Colucci G, et al. Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge. Intensive Care Med. 2002;28:1419-1425.
10. Kramer L, Bauer E, Joukhadar C, et al. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. Crit Care Med. 2003;31:2450-2455.
11. Flanigan MJ, Pillsbury L, Sadewasser G, et al. Regional hemodialysis anticoagulation: hypertonic tri-sodium citrate or anticoagulant citrate dextrose-A. Am J Kidney Dis. 1996;27:519-524.
12. Kamath PS, Kim WR. Advanced Liver Disease Study G: The model for end-stage liver disease (MELD). Hepatology. 2007;45:797-805.
13. Morgera S, Scholle C, Voss G, et al. Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: single-center experience. Nephron. 2004;97:131-136.
14. Kutsogiannis DJ, Gibney RT, Stollery D, et al. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int. 2005;67: 2361-2367.
15. Meier-Kriesche HU, Gitomer J, Finkel K, et al. Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. Crit Care Med. 2001;29:748-752.
16. Burry LD, Tung DD, Hallett D, et al. Regional citrate anticoagulation for PrismaFlex continuous renal replacement therapy. Ann Pharmacother. 2009;43:1419-1425.
17. Amitrano L, Guardascione MA, Brancaccio V, et al. Coagulation disorders in liver disease. Semin Liver Dis. 2002;22: 83-96.
18. Agarwal B, Shaw S, Hari MS, et al. Continuous renal replacement therapy (CRRT) in patients with liver disease: is circuit life different? J Hepatol. 2009;51:504-509.
19. Dorval M, Madore F, Courteau S, et al. A novel citrate anticoagulation regimen for continuous venovenous hemodiafiltration. Intensive Care Med. 2003;29:1186-1189.
20. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology. 2003;124:91-96.